🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise globally, with data suggesting in excess of 82 million instances annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on findings released by a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which combines two antibiotics. The trial included nearly 1,000 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Doctors treating patients have shared positive views. Having a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea globally.